Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting

PLoS Medicine

Volumn 5, Issue 1, 2008, Pages 0123-0138

  Pietras, Kristian ^a,b   Pahler, Jessica ^a   Bergers, Gabriele ^a   Hanahan, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; IMATINIB; KERATINOCYTE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; ESTRADIOL; FGF7 PROTEIN, MOUSE; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR; TUMOR PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; FEMALE; MORNING DOSAGE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN FUNCTION; UTERINE CERVIX CANCER; ANIMAL; BIOSYNTHESIS; CARCINOMA; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EPITHELIUM CELL; FIBROBLAST; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; METABOLISM; MOUSE STRAIN; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PERICYTE; PHYSIOLOGY; SECRETION (PROCESS); STROMA CELL; TRANSGENIC MOUSE; UTERINE CERVIX TUMOR; VASCULARIZATION; VIROLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; EPITHELIAL CELLS; ESTRADIOL; FEMALE; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 7; FIBROBLASTS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PARACRINE COMMUNICATION; PERICYTES; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STROMAL CELLS; UTERINE CERVICAL NEOPLASMS;

EID: 38849202330     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050019     Document Type: Article

References (66)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
2. De Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200: 429-447.
3. Tlsty TD, Hein PW (2001) Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11: 54-59.
4. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337.
5. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, et al. (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851.
6. Micke P, Ostman A (2005) Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9: 1217-1233.
7. Joyce JA (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell 7: 513-520.
8. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, et al. (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6: 17-32.
9. Chen Y, Miller C, Mosher R, Zhao X, Deeds J, et al. (2003) Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res 63: 1927-1935.
10. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, et al. (2000) Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 60: 2562-2566.
11. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, et al. (2000) Genes expressed in human tumor endothelium. Science 289: 1197-1202.
12. Park CC, Bissell MJ, Barcellos-Hoff MH (2000) The influence of the microenvironment on the malignant phenotype. Mol Med Today 6: 324-329.
13. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A (2003) PDGF receptors as cancer drug targets. Cancer Cell 3: 439-443.
14. Board R, Jayson GC (2005) Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat 8: 75-83.
15. Forsberg K, Valyi-Nagy I, Heldin C-H, Herlyn M, Westermark B (1993) Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci U S A 90: 393-397.
16. Shao Z-M, Nguyen M, Barsky SH (2000) Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19: 4337-4345.
17. Skobe M, Fusenig NE (1998) Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci U S A 95: 1050-1055.
18. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, et al. (2004) VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23: 2800-2810.
19. Tejada ML, Yu L, Dong J, Jung K, Meng G, et al. (2006) Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res 12: 2676-2688.
20. Waggoner SE (2003) Cervical cancer. Lancet 361: 2217-2225.
21. Wolf JK, Ramirez PT (2001) The molecular biology of cervical cancer. Cancer Invest 19: 621-629.
22. Arbeit JM, Munger K, Howley PM, Hanahan D (1994) Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 68: 4358-4368.
23. Arbeit JM, Howley PM, Hanahan D (1996) Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 93: 2930-2935.
24. Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114: 623-633.
25. Smith-McCune K, Zhu YH, Hanahan D, Arbeit J (1997) Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res 57: 1294-1300.
26. Van Trappen PO, Ryan A, Carroll M, Lecoeur C, Goff L, et al. (2002) A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer 87: 537-544.
27. Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, et al. (2007) Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res 67: 7113-7123.
28. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, et al. (2000) Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 60: 1267-1275.
29. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, et al. (2003) Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 63: 4862-4871.
30. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G (2000) Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 60: 7163-7169.
31. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309.
32. Sano H, Sudo T, Yokode M, Murayama T, Kataoka H, et al. (2001) Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 103: 2955-2960.
33. Li X, Pontén A, Aase K, Karlsson L, Abramsson A, et al. (2000) PDGF-C is a new protease-activated ligand for the PDGF α-receptor. Nature Cell Biol 2: 302-309.
34. Castle PE (2004) Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis 8: 224-230.
35. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295.
36. Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23: 939-952.
37. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G (2005) PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7: 870-879.
38. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502.
39. Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, et al. (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62: 5476-5484.
40. Greco A, Roccato E, Miranda C, Cleris L, Formelli F, et al. (2001) Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 92: 354-360.
41. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G (1994) Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 54: 3049-3053.
42. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, et al. (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 18: 338-340.
43. Krettek A, Ostergren-Lunden G, Fager G, Rosmond C, Bondjers G, et al. (2001) Expression of PDGF receptors and ligand-induced migration of partially differentiated human monocyte-derived macrophages. Influence of IFN-gamma and TGF-beta. Atherosclerosis 156: 267-275.
44. Kurban G, Ishiwata T, Kudo M, Yokoyama M, Sugisaki Y, et al. (2004) Expression of keratinocyte growth factor receptor (KGFR/FGFR2 IIIb) in human uterine cervical cancer. Oncol Rep 11: 987-991.
45. Fujimoto J, Ichigo S, Hori M, Hirose R, Sakaguchi H, et al. (1997) Expression of basic fibroblast growth factor and its mRNA in advanced uterine cervical cancers. Cancer Lett 111: 21-26.
46. Sliutz G, Tempfer C, Obermair A, Dadak C, Kainz C (1995) Serum evaluation of basic FGF in breast cancer patients. Anticancer Res 15: 2675-2677.
47. Turner MA, Darragh T, Palefsky JM (1997) Epithelial-stromal interactions modulating penetration of matrigel membranes by HPV 16-immortalized keratinocytes. J Invest Dermatol 109: 619-625.
48. Uhlen M (2007) Mapping the human proteome using antibodies. Mol Cell Proteomics 6: 1455-1456.
49. Taja-Chayeb L, Chavez-Blanco A, Martinez-Tlahuel J, Gonzalez-Fierro A, Candelaria M, et al. (2006) Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int 6: 22.
50. Heldin C-H, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
51. Furuhashi M, Sjoblom T, Abramsson A, Ellingsen J, Micke P, et al. (2004) Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 64: 2725-2733.
52. Gerhardt H, Betsholtz C (2003) Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314: 15-23.
53. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW (2004) Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res 299: 286-293.
54. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, et al. (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715-725.
55. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105: 1589-1594.
56. Ikeda Y, Hayashi I, Kamoshita E, Yamazaki A, Endo H, et al. (2004) Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 64: 5178-5185.
57. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
58. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, et al. (2003) Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197: 221-232.
59. Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, et al. (1999) Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol 10: 707-713.
60. Bhardwaj B, Klassen J, Cossette N, Sterns E, Tuck A, et al. (1996) Localization of platelet-derived growth factor β receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 2: 773-782.
61. Lindmark G, Sundberg C, Glimelius B, Påhlman L, Rubin K, et al. (1993) Stromal expression of platelet-derived growth factor β-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest 69: 682-689.
62. Sundberg C, Branting M, Gerdin B, Rubin K (1997) Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Transfer of platelet-derived growth factor-AB/BB to stromal cells. Am J Pathol 151: 479-492.
63. Kawai T, Hiroi S, Torikata C (1997) Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 77: 431-436.
64. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, et al. (2003) Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95: 458-470.
65. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
66. Eriksson A, Siegbahn A, Westermark B, Heldin C-H, Claesson-Welsh L (1992) PDGFα- and β-receptors activate unique and common signal transduction pathways. EMBO J 11: 543-550.